Dissecting the mechanism of cabozantinib anti-tumor effect in renal cancer

解析卡博替尼抗肾癌作用机制

基本信息

  • 批准号:
    10443836
  • 负责人:
  • 金额:
    $ 22.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-02 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT With 5-year survival rates of 10-15%, metastatic renal cell carcinoma (RCC) is largely incurable. Tyrosine kinase inhibitors (TKIs) are the largest and most widely used class of drugs for RCC treatment (6 FDA-approved drugs), but resistance routinely develops. The first TKIs were approved by the FDA nearly 2 decades ago, but how resistance arises has remained a mystery. RCC TKIs were developed to target vascular endothelial growth factor receptor 2 (VEGFR2), which plays a critical role in angiogenesis and RCC biology. However, a role for VEGFR2 in mediating the anti-tumor response remains to be demonstrated, and most RCC TKIs target multiple other kinases. Understanding resistance mechanisms has been instrumental in dissecting how oncology drugs precisely work. As such, how RCC TKIs function remains enigmatic and this represents a significant, longstanding, and critical knowledge gap. Furthermore, understanding how kinase inhibitors exert their anti- tumor effect and how resistance develops often yields new avenues for drug development. Indeed, relevant targets for other kinase inhibitors have been identified and validated across multiple tumor types, which has enabled the development of second- and third-generation inhibitors. This proposal seeks to understand how cabozantinib, arguably the most potent FDA-approved TKI for RCC, functions to inhibit tumor growth and how resistance develops. Cabozantinib inhibits a family of tumor-driving kinases with roles in tumor cells (such as AXL, MET, RET and KIT) and the tumor microenvironment (such as VEGFR2). One potential explanation for why it remains to be determined how RCC TKIs function is that inhibition of kinases in the tumor microenvironment (TME) plays a critical role in their anti-tumor effects. This proposal will evaluate not only how cabozantinib affects tumor cells, but also how it affects the TME. However, dissecting the role of the TME in the anti-tumor response is challenging and innovative approaches are needed. The proposal will leverage a pioneering mouse model to dissect, for the first time, the role of the TME in mediating cabozantinib anti-tumor response. If successful, these studies will establish how cabozantinib exerts its anti-tumor activity. By defining how cabozantinib functions and how resistance is acquired, we will be poised to develop strategies to overcome resistance. The innovative paradigm presented herein has broad application to dissecting the role of the microenvironment in mediating the action of any cancer drug, and the ensuing discoveries may pave the way for the next generation of inhibitors and enable rational combinations.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Brugarolas其他文献

James Brugarolas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Brugarolas', 18)}}的其他基金

Dissecting the mechanism of cabozantinib anti-tumor effect in renal cancer
解析卡博替尼抗肾癌作用机制
  • 批准号:
    10289979
  • 财政年份:
    2021
  • 资助金额:
    $ 22.54万
  • 项目类别:
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
  • 批准号:
    9071063
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
  • 批准号:
    9752982
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10708855
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
  • 批准号:
    10706530
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
Project 1: Targeting HIF2 in Renal Cell Carcinoma
项目 1:针对肾细胞癌中的 HIF2
  • 批准号:
    10708828
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
Core A: Administrative Core
核心A:行政核心
  • 批准号:
    10708829
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    9071068
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
Core A: Administrative Core
核心A:行政核心
  • 批准号:
    9071064
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
Evaluation of the BAP1 tumor suppressor gene in renal cell carcinoma
BAP1抑癌基因在肾细胞癌中的评价
  • 批准号:
    9008030
  • 财政年份:
    2013
  • 资助金额:
    $ 22.54万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 22.54万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 22.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 22.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 22.54万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 22.54万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 22.54万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 22.54万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 22.54万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 22.54万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 22.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了